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rapid release of the drug whereas other modalities can have sustained 
drug delivery. The speakers in this forum will describe the pros and 
cons of each of the drug delivery systems that are designed to 
improve bioavailability of cancer chemotherapy to sites of neoplasia. 
X-ray guided drug delivery exploits the stress response within cancer 
that occurs during radiotherapy. Low doses of radiation induce DNA 
strand breaks and oxidative stress within cancer. Stress proteins such 
as GRP78, TIP1 and Calreticulin are induced and transported to the 
surface of cancer cells following irradiation. Antibodies and peptide 
ligands that are specific to these radiation inducible neoantigens are 
used to coat the surface of nanoparticles and liposomes for guided 
drug delivery. This strategy of x-ray guided drug delivery is analogous 
to military use of lasers to tag targets for smart bombs. X-rays are 
tissue penetrating and therefore tag deep seated cancers for the 
binding of antibodies and peptide ligands. The discovery platform for 
this technology identifies inducible antigens that are specific to 
cancer and not induced in normal tissues. Antigens that are induced in 
normal tissues are discarded while cancer specific antigens are 
developed. These targeting moieties are conjugated to drug delivery 
systems. In contrast, hyperthermia is used to heat a tumor. As 
liposomes pass through the tumors, the lipids melt and release the 
drug in that volume. This strategy of thermal regulation of drug 
delivery has entered Phase III clinical trials in breast cancer to deliver 
Doxorubicin. The use of magnetic nanoparticles for drug delivery is 
still in the preclinical stage. Paramagnetic nanoparticles have been 
targeted to tumors for both drug delivery and to heat tumors. 
Oscillating magnetic fields cause these nanoparticles to vibrate and 
heat the tumor to induce hyperthermia. These three forms of image 
guided drug delivery will becompared and contrasted during the 
debate of the practicality of bringing these new strategies of drug 
delivery into clinical trials.  
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Proton beam therapy seems to offer significant advantages over 
conventional techniques especially for the pediatric cohort and the 
number of children being treated with proton therapy for solid tumors 
is increasing rapidly throughout the world. There have been multiple 
dosimetric studies clearly demonstrating that protons decrease the 
irradiated volume and therefore the dose to the developing normal 
tissues compared with photon techniques while showing excellent 
outcome in the pediatric population. As in paediatric malignancies 
survival rates have increased considerably, from 0-20% until the 50ies 
up to about 80% today, quality of life (QoL) and late sequelae have 
become a major concern in pediatric cancer survivors. Therefore, 
proton therapy was understood as a tool potentially reducing the risk 
for secondary malignancy induction as well as for late effects. As 
children are particularly sensitive to radiation injury, they seem to be 
the cohort taking the greatest potential benefit from sparing dose to 
normal tissue. Today, local treatment with proton beam in CNS 
tumors or sarcomas is a common choice to be offered to the pediatric 
cohort in Europe and in US whenever available. 
It is suggested from early reports, that secondary cancer incidence 
may be reduced by 50% when using proton therapy. Additional early 
data was published on neurocognitive functioning and quality of life, 
both suggesting favourable outcome after proton beam therapy. Still, 
prospective data are limited, cohorts are small and observation times 
not sufficient, especially when looking at very young children being 
treated with proton beam therapy. 
In conclusion, proton beam therapy is a promising tool to explore 
particularly in the pediatric cohort to reduce the risk for late effects 
and secondary malignancies; however, due to limited availability up 
to now, clinical experience of proton therapy in childhood cancer is 
still limited. Therefore, all pediatric programs should be accompanied 
by prospective evaluations of late effects and QoL to gather more 
information on optimal use of proton therapy. Due to small number of 
patients and ethical considerations, randomized data will be hardly 
available even on the long term in children. Still, more clinical data 
will be emerging to quantify the clinical benefit of proton beam 
therapy with regard to a decrease in late effects while maintaining 
excellent cancer control rates.  
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Purpose/Objective: The aim of this study is to investigate the 
predictive value of the modelled tumour control probability (TCP) 
based on BED calculations using individual measurements of in vitro 
radiosensitivity (SF2) and potential doubling time (Tpot) for head and 
neck (H&N) cancer patients versus literature-based average 
radiobiological parameters. 
Materials and Methods: Tumour radiosensitivity, measured in vitro on 
primary biopsies and expressed as surviving fraction of cells following 
an acute exposure of 2 Gy (SF2), Tpot and tumour size were determined 
for 46 H&N cancer patients. All patients were treated with external 
beam radiotherapy and 28 patients also received brachytherapy. For 
each patient TCP was calculated using a Poisson-LQ model based 
either on the patient-specific radiobiological parameters or literature-
based average radiobiological parameters (α=0.3 Gy-1 and Tpot=3 days). 
The predicted TCP values for the two sets of parameters were 
compared with the actual outcome for the patients in terms of local 
control. 
Results: The average radiobiological parameters lead to a large 
underestimationof TCP as the predicted TCP was below 10% for the 
majority of the patients that actually presented local control. When 
tumour specific parameters were used,the majority of the patients 
with local control had a predicted TCP larger than 90%. 
A Receiver Operating Characteristic (ROC) curve analysis was also 
performed for assessing the predictive values of the two methods for 
calculating the TCP. The corresponding ROC curves are shown in 
Figure 1. 
